ArticleNature communications2022
Persister state-directed transitioning and vulnerability in melanoma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 35 citations in OpenAlex.
- MAPK Inhibitor-Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities.Cancer science · 2026Review
- Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.EMBO molecular medicine · 2026Article
- Plasticity, signaling, and metabolic rewiring in melanoma persister cells.Communications biology · 2026Review
- The role of KDM5B in creating synthetic vulnerabilities in combination with radiotherapy in melanoma cells.Cell communication and signaling : CCS · 2026Article
- Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.Leukemia · 2026Article
- Multiplexed enrichment and tracking of lineages with CloneSweeper.bioRxiv : the preprint server for biology · 2026Article
- Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications.Oncology research · 2026Review
- Multidimensional tumor heterogeneity and its role in therapeutic resistance.Frontiers in immunology · 2026Review
- Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma.Nature communications · 2025Article
- Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.Molecular cancer · 2025Review
- Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma.Cancer research · 2025Article
- Endothelial KDM5B Regulated by Piezo1 Contributes to Disturbed Flow Induced Atherosclerotic Plaque Formation.Journal of cellular and molecular medicine · 2024Article
- ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma.Cell reports · 2024Article
- Article
- Real-Time Cell Cycle Imaging in a 3D Cell Culture Model of Melanoma, Quantitative Analysis, Optical Clearing, and Mathematical Modeling.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells.Frontiers in cell and developmental biology · 2024Article
- Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy.Cell death & disease · 2023Article
- Drug-tolerant persister cells in cancer: the cutting edges and future directions.Nature reviews. Clinical oncology · 2023Review
- Article
- Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.Nature cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 11 institutions in 4 countries.
Heike ChauvistréDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-7703-1054
Batool ShannanDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.
Sheena M Daignault-MillThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.
Robert J JuThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.
Daniel PicardGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, Germany.
Stefanie EgetemaierDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-6871-5980
Renáta VáraljaiDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0001-6852-6859
Christine S GibhardtMolecular Physiology, Institute of Cardiovascular Physiology, University Medical Center, Georg-August-University, Göttingen, Germany.ORCID 0000-0001-5104-970X
Antonio SechiInstitute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Medical School, Aachen, Germany.ORCID 0000-0002-1374-1794
Farnusch KaschaniDepartment of Chemical Biology, Faculty of Biology, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0001-6572-3232
Oliver KeminerFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Schnackenburgallee 114, 22525, Hamburg, Germany.ORCID 0000-0003-1473-469X
Samantha J StehbensThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-8145-2708
Qin LiuThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-9964-580X
Xiangfan YinThe Wistar Institute, Philadelphia, PA, USA.
Kirujan JeyakumarFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227, Dortmund, Germany.ORCID 0000-0002-0184-6775
Felix C E VogelDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0003-4067-2074
Clemens KreplerThe Wistar Institute, Philadelphia, PA, USA.
Vito W RebeccaThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-8124-0900
Linda KubatGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, Germany.ORCID 0000-0001-7046-2663
Smiths S LueongGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, Germany.
Jan ForsterGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, Germany.
Susanne HornDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.
Marc RemkeGerman Consortium for Translational Cancer Research (DKTK), Partner Site Essen/Düsseldorf, Essen/Düsseldorf, Germany.
Michael EhrmannCenter for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-1927-260X
Annette PaschenDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0003-1651-1262
Jürgen C BeckerDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0001-9183-653X
Iris HelfrichDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.
Daniel RauhFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227, Dortmund, Germany.ORCID 0000-0002-1970-7642
Markus KaiserDepartment of Chemical Biology, Faculty of Biology, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-6540-8520
Sheraz GulFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Schnackenburgallee 114, 22525, Hamburg, Germany.ORCID 0000-0003-2543-1643
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0003-0839-0739
Ivan BogeskiMolecular Physiology, Institute of Cardiovascular Physiology, University Medical Center, Georg-August-University, Göttingen, Germany.
José Neptuno Rodríguez-LópezGENZ-Group of Research on Enzymology, Department of Biochemistry and Molecular Biology-A, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Murcia, Spain.ORCID 0000-0001-6863-1173
Nikolas K HaassThe University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-3928-5360
Dirk SchadendorfDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany.ORCID 0000-0003-3524-7858
Alexander RoeschDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, Germany. alexander.roesch@uk-essen.de.ORCID 0000-0002-0773-6067
The Wistar Institute · USEssen University Hospital · DEThe University of Queensland · AUUniversity of Duisburg-Essen · DEGerman Cancer Research Center · DEFraunhofer Institute for Translational Medicine and Pharmacology · DETU Dortmund University · DEUniversity of Göttingen · DERWTH Aachen University · DEUniversidad de Murcia · ESWest Cancer Center · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Michael Davies · 2017 to 2026
$13.9MTargeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2021 to 2025
$11.3MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MUnderstanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in MelanomaR01CA238237 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HERLYN, MEENHARD F, RAJ, ARJUN · 2020 to 2024
$2.9MNCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS P50 CA261608NCI NIH HHS R01 CA238237NCI NIH HHS U54 CA224070
Abstract
Melanoma is a highly plastic tumor characterized by dynamic interconversion of different cell identities depending on the biological context. Melanoma cells with high expression of the H3K4 demethylase KDM5B (JARID1B) rest in a slow-cycling, yet reversible persister state. Over time, KDM5B
Indexed as
MelanomaMonophenol MonooxygenaseCell Line, TumorCell ProliferationHumansMelanocytesMonophenol Monooxygenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.